- Home
- NRIX vs KRUS Comparison
NRIX vs KRUS Comparison
Compare NRIX & KRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- KRUS
- Stock Information
- Founded
- NRIX 2009
- KRUS 2008
- Country
- NRIX United States
- KRUS United States
- Employees
- NRIX N/A
- KRUS N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- KRUS Restaurants
- Sector
- NRIX Health Care
- KRUS Consumer Discretionary
- Exchange
- NRIX Nasdaq
- KRUS Nasdaq
- Market Cap
- NRIX 952.9M
- KRUS 911.2M
- IPO Year
- NRIX 2020
- KRUS 2019
- Fundamental
- Price
- NRIX $11.49
- KRUS $78.71
- Analyst Decision
- NRIX Strong Buy
- KRUS Buy
- Analyst Count
- NRIX 16
- KRUS 9
- Target Price
- NRIX $30.44
- KRUS $74.67
- AVG Volume (30 Days)
- NRIX 796.7K
- KRUS 273.4K
- Earning Date
- NRIX 07-10-2025
- KRUS 07-08-2025
- Dividend Yield
- NRIX N/A
- KRUS N/A
- EPS Growth
- NRIX N/A
- KRUS N/A
- EPS
- NRIX N/A
- KRUS N/A
- Revenue
- NRIX $56,417,000.00
- KRUS $258,444,000.00
- Revenue This Year
- NRIX $16.69
- KRUS $19.52
- Revenue Next Year
- NRIX N/A
- KRUS $18.63
- P/E Ratio
- NRIX N/A
- KRUS N/A
- Revenue Growth
- NRIX N/A
- KRUS 21.37
- 52 Week Low
- NRIX $8.18
- KRUS $40.03
- 52 Week High
- NRIX $29.56
- KRUS $110.66
- Technical
- Relative Strength Index (RSI)
- NRIX 50.78
- KRUS 60.33
- Support Level
- NRIX $12.25
- KRUS $75.83
- Resistance Level
- NRIX $12.00
- KRUS $83.69
- Average True Range (ATR)
- NRIX 0.69
- KRUS 4.31
- MACD
- NRIX -0.08
- KRUS -0.28
- Stochastic Oscillator
- NRIX 21.57
- KRUS 65.68
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About KRUS Kura Sushi USA Inc.
Kura Sushi USA Inc is a technology-enabled restaurant concept serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. It offers several dishes, including Dashi Olive Salmon, Tomago, Sweet Shrimp, Tuna, Garlic Tuna Steak, and Salmon, among others.